Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation

Summary

PCI (optimal catheter-based coronary revascularization) + intensive medical therapy is superior to intensive medical therapy alone using the combined endpoint of all-cause mortality or nonfatal MI.

Conditions

• Myocardial Ischemia

Interventions

PROCEDURE

Intensive medical therapy

PROCEDURE

Percutaneous Coronary Intervention (PCI) plus intensive medical therapy

Sponsors & Collaborators

• Medical Research Council of Canada

  collaborator OTHER

• Merck Sharp & Dohme LLC

  collaborator INDUSTRY

• Pfizer

  collaborator INDUSTRY

• GE Healthcare

  collaborator INDUSTRY

• Bristol-Myers Squibb

  collaborator INDUSTRY

• Astellas Pharma Inc

  collaborator INDUSTRY

• AstraZeneca

  collaborator INDUSTRY

• Sanofi

  collaborator INDUSTRY

• Datascope Corp.

  collaborator INDUSTRY

• First Horizon

  collaborator UNKNOWN

• Kos

  collaborator UNKNOWN

• Key Pharmaceuticals

  collaborator INDUSTRY

• Integrated Therapeutics Group

  collaborator INDUSTRY

• Hoest-Marion-Roussel

  collaborator UNKNOWN

• US Department of Veterans Affairs

  lead FED

Principal Investigators

• William E. Boden · VA South Texas Health Care System, San Antonio

Study Design

Allocation

RANDOMIZED

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

1998-12-31

Completion

2006-06-30

Countries

• United States
• Canada

Study Locations